Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Interventional Cardiology: Current Challenges in Acute Myocardial Infarction
share announcement

Interventional Cardiology: Current Challenges in Acute Myocardial Infarction

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (20 April 2022) | Viewed by 17197

Special Issue Editor

Prof. Dr. Andreas Schäfer

E-Mail Website
Guest Editor
Department of Cardiology & Angiology, Hannover Medical School, Hannover, Germany
Interests: acute myocardial infarction; cardiac arrest; cardiogenic shock; mechanical circulatory support

Special Issue Information

Dear Colleagues,

In this Special Issue, we will discuss current challenges to reducing reperfusion injury in stable patients with large myocardial infarction, including therapeutic hypothermia, super-saturated oxygen therapy, and unloading by Impella. To improve care for patients with infarct-related cardiogenic shock, we will discuss the relevance of achieving complete revascularization as well as the topic of mechanical circulatory support by either Impella or ECMO. For patients in refractory cardiac arrest, we would like to explore the potential role of ECMO-CPR (eCPR). Furthermore, the impact of the current COVID-19 pandemic on acute coronary interventions and shock treatment will be discussed. 

Prof. Dr. Andreas Schäfer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mechanical circulatory support
  • cardiogenic shock
  • reperfusion injury
  • myocardial infarction

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

3 pages, 185 KiB  
Editorial
Interventional Cardiology: Current Challenges in Acute Myocardial Infarction
by Andreas Schäfer
J. Clin. Med. 2022, 11(15), 4504; https://doi.org/10.3390/jcm11154504 - 02 Aug 2022
Viewed by 1075
Abstract
Welcome to the Special Issue “Interventional cardiology: current challenges in acute myocardial infarction” in the Journal of Clinical Medicine [...] Full article
(This article belongs to the Special Issue Interventional Cardiology: Current Challenges in Acute Myocardial Infarction)

Review

Jump to: Editorial

15 pages, 1094 KiB  
Review
When to Achieve Complete Revascularization in Infarct-Related Cardiogenic Shock
by Giulia Masiero, Francesco Cardaioli, Giulio Rodinò and Giuseppe Tarantini
J. Clin. Med. 2022, 11(11), 3116; https://doi.org/10.3390/jcm11113116 - 31 May 2022
Cited by 6 | Viewed by 2987
Abstract
Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) is a life-threatening condition frequently encountered in patients with multivessel coronary artery disease (CAD). Despite prompt revascularization, in particular, percutaneous coronary intervention (PCI), and therapeutic and technological advances, the mortality rate for patients with [...] Read more.
Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) is a life-threatening condition frequently encountered in patients with multivessel coronary artery disease (CAD). Despite prompt revascularization, in particular, percutaneous coronary intervention (PCI), and therapeutic and technological advances, the mortality rate for patients with CS related to AMI remains unacceptably high. Differently form a hemodynamically stable setting, a culprit lesion-only (CLO) revascularization strategy is currently suggested for AMI–CS patients, based on the results of recent randomized evidence burdened by several limitations and conflicting results from non-randomized studies. Furthermore, mechanical circulatory support (MCS) devices have emerged as a key therapeutic option in CS, especially in the case of their early implantation without delaying revascularization and before irreversible organ damage has occurred. We provide an in-depth review of the current evidence on optimal revascularization strategies of multivessel CAD in infarct-related CS, assessing the role of different types of MCS devices and highlighting the importance of shock teams and medical care system networks to effectively impact on clinical outcomes. Full article
(This article belongs to the Special Issue Interventional Cardiology: Current Challenges in Acute Myocardial Infarction)
►▼ Show Figures

Figure 1

8 pages, 940 KiB  
Review
Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock
by Jacob Eifer Møller, Jesper Kjaergaard, Christian Juhl Terkelsen and Christian Hassager
J. Clin. Med. 2022, 11(9), 2427; https://doi.org/10.3390/jcm11092427 - 26 Apr 2022
Cited by 5 | Viewed by 2782
Abstract
Acute myocardial infarction complicated by cardiogenic shock (AMICS), is characterized by critically low cardiac output and decreased myocardial contractility. In this situation, a treatment that unloads the myocardium and restores CO without increasing the myocardial oxygen demand is theoretically appealing. Axial flow pumps [...] Read more.
Acute myocardial infarction complicated by cardiogenic shock (AMICS), is characterized by critically low cardiac output and decreased myocardial contractility. In this situation, a treatment that unloads the myocardium and restores CO without increasing the myocardial oxygen demand is theoretically appealing. Axial flow pumps offer hemodynamic support without increasing myocardial oxygen consumption. Consequently, the use of axial flow pumps, especially the Impella devices, is increasing. It is likely that the SCAI C patient with predominantly left ventricular failure and without prolonged cardiac arrest is the best candidate for these devices. Registry data suggest that pre-PCI Impella may be advantageous to post-PCI placement. However, several gaps in knowledge exist regarding optimal patient selection, futility criteria, timing, weaning and escalation strategy, and until data from adequately sized randomized trials are available, immediate individual evaluation for mechanical circulatory support by a shock team is warranted when a patient is diagnosed with AMICS. Full article
(This article belongs to the Special Issue Interventional Cardiology: Current Challenges in Acute Myocardial Infarction)
►▼ Show Figures

Figure 1

10 pages, 239 KiB  
Review
Intracoronary Application of Super-Saturated Oxygen to Reduce Infarct Size Following Myocardial Infarction
by Andreas Schäfer, Muharrem Akin, Johanna Diekmann and Tobias König
J. Clin. Med. 2022, 11(6), 1509; https://doi.org/10.3390/jcm11061509 - 09 Mar 2022
Cited by 6 | Viewed by 4378
Abstract
Optimal medical therapy for secondary prevention following acute myocardial infarction reduces non-fatal ischaemic events. Intensive antithrombotic or lipid-lowering approaches have failed to significantly lower mortality. In the past, reduction of infarct size in patients undergoing primary percutaneous revascularisation for acute myocardial infarction had [...] Read more.
Optimal medical therapy for secondary prevention following acute myocardial infarction reduces non-fatal ischaemic events. Intensive antithrombotic or lipid-lowering approaches have failed to significantly lower mortality. In the past, reduction of infarct size in patients undergoing primary percutaneous revascularisation for acute myocardial infarction had been considered as a surrogate outcome marker. However, infarct size measured by magnetic resonance imaging or SPECT is strongly associated with all-cause mortality and hospitalization for heart failure within the first year after an acute myocardial infarction. Intracoronary administration of super-saturated oxygen (SSO2) immediately after revascularisation is an approach that can be used to reduce infarct size and, therefore, improve cardiovascular outcome in patients with acute myocardial infarction. In this article, we describe the modulation of pathophysiology by SSO2, review the existing trial data and present our first impressions with the technique in real clinical practice. Full article
(This article belongs to the Special Issue Interventional Cardiology: Current Challenges in Acute Myocardial Infarction)
14 pages, 1139 KiB  
Review
Extracorporeal Membrane Oxygenation in Infarct-Related Cardiogenic Shock
by Anne Freund, Steffen Desch, Janine Pöss, Dmitry Sulimov, Marcus Sandri, Nicolas Majunke and Holger Thiele
J. Clin. Med. 2022, 11(5), 1256; https://doi.org/10.3390/jcm11051256 - 25 Feb 2022
Cited by 5 | Viewed by 3471
Abstract
Mortality in infarct-related cardiogenic shock (CS) remains high, reaching 40–50%. In refractory CS, active mechanical circulatory support devices including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are rapidly evolving. However, supporting evidence of VA-ECMO therapy in infarct-related CS is low. The current review aims to [...] Read more.
Mortality in infarct-related cardiogenic shock (CS) remains high, reaching 40–50%. In refractory CS, active mechanical circulatory support devices including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are rapidly evolving. However, supporting evidence of VA-ECMO therapy in infarct-related CS is low. The current review aims to give an overview on the basics of VA-ECMO therapy, current evidence, ongoing trials, patient selection and potential complications. Full article
(This article belongs to the Special Issue Interventional Cardiology: Current Challenges in Acute Myocardial Infarction)
►▼ Show Figures

Figure 1

9 pages, 1752 KiB  
Review
Hypothermia for Cardioprotection in Patients with St-Elevation Myocardial Infarction: Do Not Give It the Cold Shoulder Yet!
by Mohamed El Farissi, Thomas P. Mast, Mileen R. D. van de Kar, Daimy M. M. Dillen, Jesse P. A. Demandt, Fabienne E. Vervaat, Rob Eerdekens, Simon A. G. Dello, Danielle C. Keulards, Jo M. Zelis, Marcel van ‘t Veer, Frederik M. Zimmermann, Nico H. J. Pijls and Luuk C. Otterspoor
J. Clin. Med. 2022, 11(4), 1082; https://doi.org/10.3390/jcm11041082 - 18 Feb 2022
Cited by 7 | Viewed by 1710
Abstract
The timely revascularization of an occluded coronary artery is the cornerstone of treatment in patients with ST-elevation myocardial infarction (STEMI). As essential as this treatment is, it can also cause additional damage to cardiomyocytes that were still viable before reperfusion, increasing infarct size. [...] Read more.
The timely revascularization of an occluded coronary artery is the cornerstone of treatment in patients with ST-elevation myocardial infarction (STEMI). As essential as this treatment is, it can also cause additional damage to cardiomyocytes that were still viable before reperfusion, increasing infarct size. This has been termed “myocardial reperfusion injury”. To date, there is still no effective treatment for myocardial reperfusion injury in patients with STEMI. While numerous attempts have been made to overcome this hurdle with various experimental therapies, the common denominator of these therapies is that, although they often work in the preclinical setting, they fail to demonstrate the same results in human trials. Hypothermia is an example of such a therapy. Although promising results were derived from experimental studies, multiple randomized controlled trials failed to do the same. This review includes a discussion of hypothermia as a potential treatment for myocardial reperfusion injury, including lessons learned from previous (negative) trials, advanced techniques and materials in current hypothermic treatment, and the possible future of hypothermia for cardioprotection in patients with STEMI. Full article
(This article belongs to the Special Issue Interventional Cardiology: Current Challenges in Acute Myocardial Infarction)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop